LIVE ATTENUATED ZIKA VIRUS VACCINE

The present disclosure relates to attenuated Zika viruses and vaccines, attenuated chimeric Zika viruses and vaccines, and to multivalent immunogenic compositions comprising Zika vaccines and vaccinesto other flavi viruses. The chimeric Zika viruses includes a first nucleotide sequence encoding at least one structural protein from a Zika virus (ZIKV), a second nucleotide sequence encoding at least one nonstructural protein from a first flavi virus, and a third nucleotide sequence of a (3') untranslated region from a second flavi virus. The multivalent immunogenic compositions comprise an attenuated ZIKV vaccine or an attenuated chimeric ZIKV vaccine (or their combination) together with one or more of a first attenuated virus that is immunogenic against dengue serotype (1), a second attenuated virus that is immunogenic against dengue serotype (2), a third attenuated virus that is immunogenic against dengue serotype (3), and a fourth attenuated virus that is immunogenic against dengue serotype (4). The present